Note: The contents of this blog are for informational purposes only and should not be construed as medical advice or substitute for professional care. For medical emergencies, dial 911!
Orplatna cancer drug under FDA advisory panel srutiny
Posted Jul 25th 2007 1:01PM by Brian White
Filed under: Prostate Cancer, Drug
With prostate cancer being one of the most deadly forms for men to suffer from, the introduction of more pharmaceutical drugs that specifically treat prostate cancer are sure to increase.
One of the first such subjects is GPC Biotech AG's Orplatna, which is getting a reprieve by and FDA advisory panel. The panel suggested to the FDA that more evidence (like clinical trials, I suppose) is needed
before Orplatna is approved for use in the U.S. for prostate cancer patients.
The panel suggested that data needed to be shown that showed whether or not Orplatna-using patients lived longer than others who received a placebo. In other words, hard data on survival rate needs to be shown, and GPC Biotech AG's response is that it will take at least a year for that to become available.
Tags: cancer drug, CancerDrug, orplatna, prostate cancer, ProstateCancer
Please keep your comments relevant to this blog entry. Email addresses are never displayed, but they are required to confirm your comments.
When you enter your name and email address, you'll be sent a link to confirm your comment, and a password. To leave another comment, just use that password.
To create a live link, simply type the URL (including http://) or email address and we will make it a live link for you. You can put up to 3 URLs in your comments. Line breaks and paragraphs are automatically converted — no need to use <p> or <br> tags.
